Vanda Pharmaceuticals (VNDA) Reports Positive Phase III Results for HETLIOZ in DSWPD

gurufocus.com · 2026-09-30

On September 30, 2026, Vanda Pharmaceuticals Inc (NASDAQ: VNDA) announced encouraging topline results from its pivotal Phase III trial evaluating HETLIOZ (tasim

TickrTrends take: Positive Phase III results for HETLIOZ in delayed sleep-wake phase disorder could support revenue growth and strengthen VNDA's pipeline, which may be relevant as TickrTrends currently identifies the stock as undervalued within the Healthcare sector. Clinical validation of late-stage programs can narrow valuation uncertainty, so investors focused on fundamentals should monitor whether these results translate into regulatory approval and commercial uptake that justify current market pricing. The clinical progress provides data points to assess whether the company's current valuation adequately reflects its earnings potential from approved and pipeline assets.

Read the full story at gurufocus.com →